Cargando…

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is th...

Descripción completa

Detalles Bibliográficos
Autores principales:	McFarland, Daniel C, Misiukiewicz, Krzysztof J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105272/ https://www.ncbi.nlm.nih.gov/pubmed/25053887 http://dx.doi.org/10.2147/OTT.S49430

Ejemplares similares

The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
por: Ling, Yuanna, et al.
Publicado: (2023)

Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer
por: Mu, Zhuan-Zhuan, et al.
Publicado: (2019)

Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy
por: Liu, Jierui, et al.
Publicado: (2019)

Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation
por: Schmidt, Angelica, et al.
Publicado: (2017)

Health state utility valuation in radioactive iodine-refractory differentiated thyroid cancer
por: Fordham, Beth A, et al.
Publicado: (2015)

RECIST 1.1 and serum thyroglobulin measurements in the evaluation of responses to sorafenib in patients with radioactive iodine-refractory differentiated thyroid carcinoma
por: RUAN, MAOMEI, et al.
Publicado: (2013)

SAT520 Efficacy of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers
por: Toro-Tobon, David, et al.
Publicado: (2023)

A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
por: Fleeman, Nigel, et al.
Publicado: (2019)

The efficacy of radioactive iodine for the treatment of well-differentiated thyroid cancer with distant metastasis
por: Lin, Jen-Der, et al.
Publicado: (2018)

Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis
por: Wang, Chen, et al.
Publicado: (2017)

Patient Benefit-Risk Tradeoffs for Radioactive Iodine-Refractory Differentiated Thyroid Cancer Treatments
por: Mohamed, Ateesha F., et al.
Publicado: (2015)

Neoadjuvant Therapy in Differentiated Thyroid Cancer
por: Dang, Rajan P., et al.
Publicado: (2016)

Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial
por: Huillard, Olivier, et al.
Publicado: (2019)

Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial
por: Lin, Yansong, et al.
Publicado: (2021)

Patient-Derived Papillary Thyroid Cancer Organoids for Radioactive Iodine Refractory Screening
por: Sondorp, Luc H.J., et al.
Publicado: (2020)

Sarcoidosis mimicking metastatic thyroid cancer following radioactive iodine therapy
por: Myint, Zin W., et al.
Publicado: (2015)

The Genomic Landscape of Radioactive Iodine Refractory and Avid Papillary Thyroid Carcinomas
por: Al-Kuraya, Khawla Sami, et al.
Publicado: (2021)

MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation (NCT 03244956)
por: Leboulleux, Sophie, et al.
Publicado: (2021)

Targeting GLI1 Transcription Factor for Restoring Iodine Avidity with Redifferentiation in Radioactive-Iodine Refractory Thyroid Cancers
por: Oh, Ji Min, et al.
Publicado: (2022)

Predictive Value of Clinical and Pathological Characteristics for Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma: A 16-year Retrospective Study
por: Chai, Jinyan, et al.
Publicado: (2022)

Clinical role of (18)F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer
por: Tang, Xiaowei, et al.
Publicado: (2023)

Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2011)

Rationale for therapeutic decision-making in locally advanced and metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer, starting from a clinical case
por: Silaghi, Cristina Alina, et al.
Publicado: (2021)

Radiotheragnostics Paradigm for Radioactive Iodine (Iodide) Management of  Differentiated Thyroid Cancer
por: Slonimsky, Einat, et al.
Publicado: (2020)

Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer
por: Gianoukakis, Andrew G, et al.
Publicado: (2016)

Thyroid-Associated Ophthalmopathy after Radioactive Iodine Therapy for Metastatic Follicular Thyroid Carcinoma
por: Murayama, Daisuke, et al.
Publicado: (2021)

AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer
por: Collina, Francesca, et al.
Publicado: (2019)

Radioactive Iodine Therapy of Differentiated Thyroid Carcinoma: Redesigning the Paradigm
por: Goldsmith, Stanley J.
Publicado: (2017)

Low Iodine Diet for Preparation for Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma in Korea
por: Chung, Jae Hoon
Publicado: (2013)

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma
por: Jia, Wenqing, et al.
Publicado: (2022)

Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic Disease
por: Wolfson, Robert M., et al.
Publicado: (2016)

Durable Effect of Radioactive Iodine in a Patient with Metastatic Follicular Thyroid Carcinoma
por: Carhill, Aubrey A., et al.
Publicado: (2012)

ODP532 Fractionated Radioactive Iodine Therapy in Management of Differentiated Thyroid Cancer
por: Khan, Adeel Ahmad, et al.
Publicado: (2022)

Effect of Psychological Intervention on Differentiated Thyroid Cancer Patients in the Treatment with Radioactive Iodine
por: Liu, Yan-Bin, et al.
Publicado: (2023)

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
por: Fullmer, Tanner, et al.
Publicado: (2021)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
por: Kish, Jonathan K., et al.
Publicado: (2020)

Acute Myeloid Leukemia following Radioactive Iodine Therapy for Metastatic Follicular Carcinoma of the Thyroid
por: Bishnoi, Komal, et al.
Publicado: (2023)

Radioactive Iodine Administration Is Associated with Persistent Related Symptoms in Patients with Differentiated Thyroid Cancer
por: Florenzano, Pablo, et al.
Publicado: (2016)

Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors
por: Riachy, Ruba, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e57v6bomf7sg3bmqopoijfo0c1